Background: A growing body of evidence demonstrates that the immune system contributes to the therapeutic effects of trastuzumab. We sought to determine whether autoimmune background could identify patients with HER2 positive early breast cancer (EBC) who derive differential benefit from adjuvant primary trastuzumab-based therapy. Methods: HERA (BIG 1-01) is an international, multicenter, open-label, phase 3 randomized trial of 5,102 women with HER2-positive EBC, who were enrolled after completion of their postoperative chemotherapy to receive trastuzumab for 1 year, 2 years, or no trastuzumab. In this exploratory analysis, we evaluated whether there is an interaction between autoimmune history and the magnitude of trastuzumab benefit with respect to disease-free survival (DFS) and overall survival (OS). Results: A total of 5,099 patients were included in the current analysis: 4,774 patients (93.6%) had no history of autoimmune disease at baseline while 325 patients (6.4%) had autoimmune disease history, 295 of whom had active disease. Median follow-up was 11 years (IQR 10.09-11.53); 1,631 patients experienced a DFS event and 1,037 patients experienced an OS event. Random assignment to 1 or 2 years of trastuzumab compared with no trastuzumab yielded similar reductions in the risk of events for patients with no autoimmune history as for patients with autoimmune history (interaction p ¼ 0.95 for DFS, and p ¼ 0.62 for OS). Trastuzumab reduced the risk of DFS event for both the no autoimmune (HR 0.77, 95% CI 0.69-0.85) as well as the autoimmune history group (HR 0.76, 95% CI 0.51-1.12). The risk of death was also similarly reduced for both groups: no autoimmune history: (HR 0.74, 95% CI 0.65-0.84); autoimmune history: (HR 0.65, 95% CI 0.40-1.07).
Background: While hormone receptor-positive (HRþ) and negative (HR-) HER2þ breast cancers (BC) are thought to be distinct diseases, only few studies have investigated the impact of HR status in the context of trastuzumab (TRZ)-treated BC. We evaluated the impact of HR status on outcomes of HER2þ early BC, before and after generalization of TRZ. Methods: Patients were identified from a cohort of 23,374 women who underwent primary surgery in 18 centers between 2000 and 2017. Since the year 2005 marked the generalization of TRZ, we conducted distinct analyses in patients treated between 2000 and 2004 and those treated between 2005 and 2017 . Impact of HR status analyses were done with censorship of events occurring after 5 years in both cohorts. Proportionality tests included all events. Results: Of 970 HER2þ patients, 349 were treated between 2000 and 2004 without TRZ, and 621 between 2005 and 2017, with TRZ-based adjuvant chemotherapy. Endocrine therapy was received by 92 and 94% of HRþ patients, respectively. In the first group, HR status impacted disease-free survival (DFS) in univariate analysis ; p < 0.001, log-rank test). Conversely, HR status did not significantly impact DFS in the cohort with ], p ¼ 0.414). Overall survival was also impacted by HR status in the group without TRZ (Hazard ratio: 2.49 [1.23-5.04]; p ¼ 0.009), but not in the TRZ group (0.68 [0.23-2.00]; p ¼ 0.482). These results were maintained in multivariate analysis including age, LVI, lymph node involvement, histology, grade and tumor size. Evolution of Hazard ratio over time for cumulative incidence of first recurrence according to HR status in patients without TRZ showed a non-proportionality of risks on metastatic (p ¼ 0.027, AD-test) recurrences, with a decreasing risk for HR-over time. Conversely, the analysis of cumulative incidence of first recurrence did not show such a trend in patients treated with TRZ, suggesting the proportionality of the risks over time for HR status. Conclusions: Instead patients treated without TRZ, HR status was no longer determinant of outcomes when patients received TRZ. These observations are supported by the analysis of Hazard ratio's evolution over time for cumulative incidence of first metastatic recurrence. Legal entity responsible for the study: Gilles Houvenaeghel. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. Background: SB3 has been approved by the European Commission as a biosimilar of reference trastuzumab (TRZ). Physicochemical and functional studies showed that SB3 was highly similar to TRZ. Here, the pharmacokinetic (PK) results comparing SB3 and TRZ in cynomolgus monkeys, healthy male subjects, and early breast cancer patients are reported. Methods: PK profiles were evaluated in cynomolgus monkeys following intravenous administration of 25 mg/kg of SB3 or TRZ every week for 4 weeks. In healthy male subjects, the PK equivalence between SB3 vs. EU-TRZ, between SB3 vs. US-TRZ, and between EU-TRZ vs. US-TRZ were assessed in a Phase I, 6 mg/kg single dose study. 1 The trough concentration was evaluated in a Phase III study of early breast cancer patients receiving either SB3 or EU-TRZ in combination with neoadjuvant chemotherapy. 2 Equivalence was to be concluded if the 90% confidence interval (CI) for the ratio of geometric lead squares means (LS Means) of the PK parameters were within the standard margins of 80.00% to 125.00%. Results: Maximum concentration C max , time to reach C max (T max ), and the area under the concentration-time curve from time zero to 168 hour (AUC 0-168 ) were similar in cynomolgus monkeys treated with SB3 or TRZ. In 108 healthy subjects, the 90% CIs for the AUC from time zero to infinity (AUC inf ), AUC from time zero to the last quantifiable concentration (AUC last ) and C max for all pairwise comparisons were within the pre-defined equivalence margin. The PK population in Phase III study consisted of 313 patients (SB3, n ¼ 161; TRZ¼152). Mean trough concentrations were similar from cycle 3 to 8 of SB3 ranging from 37.71 to 55.80 mg/mL and TRZ ranging from 39.83 to 53.13 mg/mL and the corresponding 90% CIs fell within the pre-defined equivalence margin. The proportion of patients with C trough exceeding 20mg/mL was similar between the treatment groups at each cycle.
Conclusions: In addition to the non-clinical study in cynomolgus monkeys, similar PK profiles were well demonstrated between SB3 and TRZ in healthy subjects and in breast cancer patients. Reference 1. Pivot X et al. Clin Ther. 2016; 38:1665-73; 2. Pivot X et al. J Clin Oncol. 2018; 36:968-74 Conclusions: A substantial increase in pCR rates was observed with dual targeting, regardless of ER and nodal status, reproducing the registration trial data in real world clinical practice. pCR rates were greatest in ER negative patients, regardless of regimen. The small subgroup most likely to achieve pCR were ER negative patients treated with TCHP.
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